Citations

Clear

499 citation(s) found for "Tracy, PB".

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, Michael W. , Dunbar, Andrew , Elshoury, Amro, Gojo, Ivana , Gundabolu, Krishna , Jain, Tania , Jamieson, Catriona , McMahon, Brandon , Oehler, Vivian G. , Pardanani, Animesh , Ranheim, Erik A. , Rein, Lindsay , Salit, Rachel B. , Snyder, David S., Stein, Brady L. , Vachhani, Pankit , Wadleigh, Martha , Walsh, Katherine, Ward, Dawn C., Bergman, Mary Anne, Sundar, Hema, Jain, Tania , Gerds, Aaron T. , Gotlib, Jason , Bose, Prithviraj , George, Tracy I. , Hexner, Elizabeth O. , Hobbs, Gabriela , Kuykendall, Andrew , Mohan, Sanjay , Oh, Stephen T. , Podoltsev, Nikolai , Talpaz, Moshe , Thota, Swapna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 4, 2020 | Volume: 18 | Issue: 9 | Pages: 1248-1269

10.6004/jnccn.2020.0042 | PMID 32886902 Get It

Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA , PDGFRB or FGFR1 or with PCM1-JAK2 . In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.
Mastocytosis
Tzankov, Alexandar , Craig, Fiona E. , Kelemen, Katalin, King, Rebecca L. , Reichard, Kaaren K. , Wang, Sa A. , Horny, Hans-Peter, Heffler, Enrico , Tzankov, Alexandar , Duncavage, Eric James , Orazi, Attilio , Quintanilla‐Martínez, Leticia , Rimsza, Lisa M. , George, Tracy I.

Mayo Clinic

American Journal of Clinical Pathology | August 28, 2020 | Volume: 155 | Issue: 2 | Pages: 239-266

10.1093/ajcp/aqaa183 | PMID 33313644 Get It

Abstract Objectives The 2019 Workshop of the Society for Hematopathology/European Association for Haematopathology received and reviewed cases covering the spectrum of mastocytosis and related diseases, including morphologic mimics, focusing on recent updates and relevant findings for pathologists. Methods The workshop panel reviewed 99 cases of cutaneous and systemic mastocytosis (SM) and SM and associated hematologic neoplasms (SM-AHN). Results Despite a common theme of KIT mutation (particularly D816V), mastocytosis is a heterogeneous neoplasm with a wide variety of presentations. This spectrum, including rare subtypes and extramedullary organ involvement, is discussed and illustrated by representative cases. Conclusions In the age of targeted treatment aimed at KIT, the accurate diagnosis and classification of mastocytosis has major implications for therapy and further interventions. Understanding the clinical, pathologic, and genetic findings of mastocytosis is crucial for selecting the proper tests to perform and subsequent arrival at a correct diagnosis in this rare disease.
Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy
Tracy, Jennifer A., Taylor, Bruce , Kiernan, Matthew C. , Dyck, Peter James , Amrami, Kimberly K. , Spinner, Robert J. , Crum, Brian A. , Kiernan, Matthew C , Mauermann, Michelle L.

Mayo Clinic

Journal of Clinical Neuromuscular Disease | August 21, 2020 | Volume: 22 | Issue: 1 | Pages: 1-10

10.1097/cnd.0000000000000279 | PMID 32833719 Get It

Abstract Objectives: The objective of the study is to distinguish the mechanisms of disease for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN), which we believe to be fundamentally different. However, distinguishing the mechanisms is more difficult when the presentation of CIDP is motor-predominant, focal, or asymmetric. Methods: We describe 3 focal, motor-predominant, representative cases that could be interpreted on clinical and/or electrophysiological grounds as either MMN or focal CIDP, and present pathological findings. Results: We highlight pathological differences in these cases, and provide an argument that CIDP and MMN are distinct entities with different pathophysiological mechanisms—chronic demyelination for CIDP, and an immune-mediated attack on paranodal motor axons for MMN. Conclusions: Based on clinical evaluation, electrophysiology, and nerve biopsy pathology, we can divide the conditions into inflammatory demyelinating neuropathy (focal CIDP) versus chronic axonal neuropathy (MMN). The divergent pathological findings provide further evidence that CIDP and MMN are fundamentally different disorders.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Fibroplasty (venoplasty) to facilitate transvenous lead placement: A single‐center experience
Kella, Danesh , Isath, Ameesh , Yasin, Omar , Padmanabhan, Deepak , Webster, Tracy L., Mulpuru, Siva K. , Cha, Yong‐Mei , Friedman, Paul A. , Kella, Danesh K , Webster, Tracy, Mulpuru, Siva K

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 8, 2020 | Volume: 31 | Issue: 9 | Pages: 2425-2430

10.1111/jce.14655 | PMID 32638422 Get It

AbstractIntroductionVenous stenosis is a well‐recognized complication of transvenous leads (TVLs) that is encountered during lead revisions or device upgrades. We here report the outcomes of TVL placement facilitated by fibroplasty or tunneling (TUN) procedure.MethodsWe conducted a single‐center retrospective cohort study of all patients undergoing TVL implantation requiring fibroplasty or TUN from 2005 to 2017. Medical records and procedure reports were reviewed for relevant data. Outcomes for fibroplasty and TUN to facilitate TVL placement were compared.ResultsSixty patients had fibroplasty and thirty‐five patients had a TUN procedure. There was no difference in procedure success rates between the two groups (97% fibroplasty vs. 100% TUN; p = .98). The fluoroscopy time was longer (fibroplasty = 39.7 ± 21.5 min vs. TUN = 29.2 ± 21.3 min; p = .01) and the total procedural time was shorter in the fibroplasty group (fibroplasty = 247 ± 77.8 min vs. TUN = 287 ± 77.1 min; p = .01). TUN was associated with a significantly higher incidence of acute complications (fibroplasty = 0 vs. TUN = 8; p = .002) most requiring invasive intervention and/or transfusion with blood products. Long‐term complications requiring additional device‐related procedures were comparable between the two groups (fibroplasty = 6 vs. TUN = 6; logrank p = .21).ConclusionsFor patients with venous stenosis requiring additional TVL, balloon fibroplasty is associated with similar rates of success and a significantly decreased incidence of acute complications when compared with subcutaneous TUN.
Effects of Losartan vs. Placebo on Pulmonary Biomarkers in HIV: A Randomized Comparison
Collins, Gary, Wendt, Christine , Rhame, Frank S., Rizza, Stacey A. , Zelalem, T., Liappis, Angelike P., Irini, S., MacDonald, David M. , Baker, Jason V. , Wolfson, Julian , Tracy, Russell P. , Deeks, Steven G. , Morse, Caryn G. , Kunisaki, Ken M.

Mayo Clinic

A108. HIV RELATED PNEUMONIA, TB, AND MYCOBACTERIAL INFECTIONS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2697-A2697

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2697 Get It

Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment
Todd, Naomi, McNally, Ross , Alqudah, Abdelrahim , Jerotić, Djurdja , Obradović, Danilo , Hoch, Denise , Hombrebueno, José R. , López–Campos, Guillermo , Watson, Chris , Gojnić-Dugalić, Miroslava , Simić, Tatjana , Krasnodembskaya, Anna , Eastwood, Kelly‐Ann , Hunter, Alyson, McCance, David R., Grieve, David , Kenny, Louise C. , McClements, Lana , Simic, Tatjana , Krasnodembskaya, Anna D , Šuvakov, Sonja , Desoyé, Gernot , Holmes, Valerie A , Young, Ian Stuart , Garovic, Vesna D. , Robson, Tracy

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 3, 2020 | Volume: 106 | Issue: 1 | Pages: 26-41

10.1210/clinem/dgaa403 | PMID 32617576 Get It

Abstract Context Preeclampsia is a leading cardiovascular complication in pregnancy lacking effective diagnostic and treatment strategies. Objective To investigate the diagnostic and therapeutic target potential of the angiogenesis proteins, FK506-binding protein like (FKBPL) and CD44. Design and Intervention FKBPL and CD44 plasma concentration or placental expression were determined in women pre- or postdiagnosis of preeclampsia. Trophoblast and endothelial cell function was assessed following mesenchymal stem cell (MSC) treatment and in the context of FKBPL signaling. Settings and Participants Human samples prediagnosis (15 and 20 weeks of gestation; n ≥ 57), or postdiagnosis (n = 18 for plasma; n = 4 for placenta) of preeclampsia were used to determine FKBPL and CD44 levels, compared to healthy controls. Trophoblast or endothelial cells were exposed to low/high oxygen, and treated with MSC-conditioned media (MSC-CM) or a FKBPL overexpression plasmid. Main Outcome Measures Preeclampsia risk stratification and diagnostic potential of FKBPL and CD44 were investigated. MSC treatment effects and FKBPL-CD44 signaling in trophoblast and endothelial cells were assessed. Results The CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of preeclampsia. At 20 weeks of gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.3-fold increased risk of preeclampsia (odds ratio = 2.3, 95% confidence interval [CI] 1.03-5.23, P = 0.04). In combination with high mean arterial blood pressure (&gt;82.5 mmHg), the risk further increased to 3.9-fold (95% CI 1.30-11.84, P = 0.016). Both hypoxia and MSC-based therapy inhibited FKBPL-CD44 signaling, enhancing cell angiogenesis. Conclusions The FKBPL-CD44 pathway appears to have a central role in the pathogenesis of preeclampsia, showing promising utilities for early diagnostic and therapeutic purposes.
Teaching NeuroImages: Amyloid myopathy
Pinto, Marcus Vinícius , Tracy, Jennifer A., Liewluck, Teerin , Pinto, Marcus V , Liewluck, T

Mayo Clinic

Neurology | July 2, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010107 | PMID 32611639 Get It